Skip to main content
PLOS One logoLink to PLOS One
. 2021 Mar 25;16(3):e0249139. doi: 10.1371/journal.pone.0249139

Comparison of 27-gauge and 25-gauge vitrectomy in the management of tractional retinal detachment secondary to proliferative diabetic retinopathy

Po-Lin Chen 1, Yan-Ting Chen 1,2,3, San-Ni Chen 1,4,5,*
Editor: Michael Mimouni6
PMCID: PMC7993849  PMID: 33765074

Abstract

Objective

To compare surgical outcomes between 27 and 25-gauge vitrectomy in proliferative diabetic retinopathy (PDR) with tractional retinal detachment (TRD)

Methods

This retrospective study was conducted to compare the intraoperative status, operation time, use of instruments, endotamponade substance, wound suture number, and iatrogenic break, between 27 and 25-gauge vitrectomy in 43 eyes afflicted by PDR with TRD. The post-surgical results, best-corrected visual acuity, intraocular pressure, recurrent vitreous haemorrhage, and re-operation rate were regularly followed up for 6 months.

Results

Patients in the 25 and the 27-gauge groups did not differ significantly in terms of pre-surgical conditions, such as age, gender, pre-existing glaucoma, best-corrected visual acuity (BCVA) and the severity of their TRD. The mean operation time was 56.7 minutes in the 27-gauge group and 63.7 minutes in the 25-gauge group (p = 0.94). There is significantly less use of micro forceps in the 27-gauge group (p = 0.004). No difference between micro scissors and chandelier usage were noted; neither was their difference in iatrogenic retinal breaks. Significantly fewer wound sutures were noted in the 27-gauge group (p < 0.001). The post-operative results revealed no significant difference in ocular hypertension, hypotony, BCVA improvement, recurrent vitreous haemorrhage and re-operation rate.

Conclusions

The 27-gauge vitrectomy system offers comparable surgical outcomes in PDR with TRD. The 27-gauge vitrectomy system is suitable for complicated retinal surgery.

Introduction

The microincisional vitrectomy system (MIVS) was first introduced 30 years ago, and it gradually evolved from 23-gauge to 25-gauge and then, in recent years, to a 27-gauge system [14]. Though there may be disagreement between retinal surgeons regarding the advantages of a smaller gauge vitrectomy, there has been a continued trend toward using a smaller gauge vitrectomy system [4].

The development of the MIVS demonstrates several advantages over the traditional 20-gauge pars plana vitrectomy (PPV), such as self-sealing transconjunctival wounds, reduced corneal astigmatism, diminished sclerotomy tissue damage, reduced conjunctival scarring, decreased post-operative inflammation and reduced post-operative hypotony [59]. In addition, the powerful endoillumination, intraoperative intraocular pressure (IOP) stabilisation system, ultra-high-speed cutter and wide-angle viewing system have expanded the boundaries for using the MIVS [9].

Since the introduction of a 27-gauge vitrectomy system, there have been several studies comparing the 27-gauge and 25-gauge system in the management of retinal diseases, including rhegmatogenous retinal detachment (RRD), epiretinal membrane and proliferative diabetic retinopathy (PDR) [1013]. In this retrospective study, we aim to compare the difference between the 27 and 25-gauge system in the management of tractional retinal detachment (TRD) secondary to PDR, to see whether the 27-gauge vitrectomy system offers advantages over the 25-gauge system in complicated retinal disease

Materials and methods

In the retrospective, observational study, 48 consecutive eyes of TRD patients secondary to PDR who were undergoing vitrectomy using either 25- or 27-gauge vitrectomy system in the Changhua Christian Hospital between March 2018 and January 2019, http://www.cch.org.tw/about/about_7.aspx?id=0117214&sno=&dr_no=117214&pid=were reviewed. We initiated searching patients’ medical records, identifying eligible patients, extracting the relevant data, and calculating the data from February 18th, 2019 to May 19th, 2020. One patient who did not complete a 6-month follow-up, two patients who had combined TRD and rhegmatogenous retinal detachment (CTRRD), and two patients who were uncooperative in undergoing complete ophthalmic examination, were excluded. Only 43 patients who were followed up postoperatively at the clinic for 6 months or more were included. All the surgeries were performed by one well-experienced retinal surgeon (SN Chen), and all the methods were carried out in accordance with relevant guidelines and regulations. This study was conducted under the approval number 191225 of the Ethical Committee of the Changhua Christian Hospital and the informed consents that clarified the permission of undergoing the surgery had been obtained from all of the patients. Other additional consents were waived by the ethics committee, because patient anonymity was maintained by the data source. All the medical records were collected since the surgery was done, between March 2018 and January 2019, and subsequent 6 months follow-up.

Patient data was recorded which included the duration of diabetes mellitus (DM), their HbA1c, age, gender, systemic disease, IOP, BCVA, the severity of TRD and pre-operative intravitreal injection (IVI) of anti-vascular endothelial growth factor (VEGF).

For the intraoperative status, we recorded the number of iatrogenic retinal breaks, iatrogenic cataract, simultaneous cataract surgery, the number of wound sutures, the substance of endotamponade (none, room air, SF6, C3F8, silicone oil), ancillary instrument usage for the removal of the fibrovascular membrane (such as micro forceps, micro scissors, chandelier lighting system; micro forceps used solely for macular pucker and internal limiting membrane (ILM) removal was not included) and operation time. Operation time, recorded by the operation video, was defined as the time between insertion and removal of the trocar. In the cases with concomitant cataract surgery, we deducted the time to perform the cataract surgery from the total operation time.

Post-operative outcomes measures included the improvement of BCVA, ocular hypotony, ocular hypertension, the presence of recurrent vitreous haemorrhage (VH), re-operation rates, and time to develop cataract. Ocular hypotony is defined as an IOP of 6 mmHg or lower, and ocular hypertension is defined as an IOP of 25 mmHg or higher [12]. VH recurred at 1 month or longer after the surgery was recorded as recurrent haemorrhage [14]. Re-operation was confined to the eyes with recurrent retinal detachment or recurrent VH, excluding the cases of post-vitrectomy cataract surgery or silicone oil removal. Time to develop cataract was defined as longest to follow-up 6 months, excluding the cases of simultaneous cataract surgery or pre-operative cataract surgery.

Staging of the severity of TRD

The severity of TRD was graded according to the previous literature as follows [15]:

  • Grade I: Multiple-point adhesion with or without one site plaque-like broad adhesion

  • Grade II: More than one broad adhesion, however, fewer than three sites located posterior to the equator

  • Grade III: More than three broad adhesion sites, located posterior to the equator or extending beyond the equator within one quadrant

  • Grade IV: Broad adhesions extending beyond the equator for more than one quadrant

Vitrectomy and use of the surgical instrument

The majority of patients had IVI of Bevacizumab (Avastin®) (79.1%) and Ranibizumab (Lucentis®) (13.3%) within 7 days before operation to minimise intraoperative bleeding [16]. The patient received the vitrectomy surgery under retrobulbar and peribulbar anaesthesia. Vitrectomy was performed using the Alcon Constellation® Vision System (Alcon Laboratories, Fort Worth, Texas, USA). The cutting rate was 7500 cuts per min (cpm) in both the 25 and 27-gauge vitrectomy, and the aspiration pressure was set at 0–650 mm Hg. The sclerotomy of all eyes was incised at an angle of 30 degrees.

During the operation, core vitrectomy was performed first. The proliferative membrane was removed by using a vitrectomy probe, micro forceps or micro scissors. The vitrector was used as a vertical scissor for delamination when the space under the proliferative membrane allowed for the entry of the vitrector. Micro scissors and micro forceps were used when the membrane could not be delaminated and removed by the vitrector. Bimanual manoeuvres with the assistance of the chandelier lighting system were used for eyes with broad and tight adhesion, or when the retina became redundant secondary to iatrogenic breaks, that the membrane could not be efficiently removed with vitrector and scissors. For eyes with macular pucker, macular pucker and ILM were removed with micro forceps. Pan-retinal photocoagulation was applied by a curved laser probe. In eyes with iatrogenic retinal breaks, air-fluid exchange with or without the help of perfluorocarbon liquid was performed followed by gas or silicone oil tamponade. Scleral would be checked at the end of surgery for leakage. Sutures with 8–0 Vicryl was performed in eyes with wound leakage. Patients were given topical 1% prednisolone acetate and 0.5% levofloxacin four times a day and 0.5% atropine sulfate two times a day, postoperatively.

Statistical analysis

Snellen BCVA was converted to logarithm of minimal angle of resolution (LogMAR) for calculation. Statistical analysis was performed using SPSS software (VER 15; SPSS, Chicago, IL). P values less than 0.05 were considered to be statistically significant.

Mann-Whitney U test was used for the comparison of numerical variables, including age, duration of DM, HbA1c, baseline BCVA, changes of BCVA, operation time, number of a wound suture and iatrogenic breaks between the two groups.

Fisher’s exact test, Pearson chi-square test and Yate’s continuity correction were used to compare the independent categorical variables in gender, pre-operative IVI of anti-VEGF, the severity of TRD, use of ancillary instruments, tamponade substances, ocular hypertension/hypotony, presence of recurrent VH and need for re-operation.

Results

There were 43 eyes from 42 patients (22 males, 21 females) that were included in this study. There were 21 eyes in the 27-gauge groups and 22 eyes in the 25-gauge group. Preoperatively, the 27-gauge group and 25-gauge group did not differ significantly in age, gender, glaucoma history, grading of TRD severity, best-corrected visual acuity (BCVA) in LogMAR, HbA1c, duration of DM, pre-operative PRP, or IVI of ant-VEGF (bevacizumab/ranibizumab/none). Demographic data of patients is listed in Table 1.

Table 1. Demographic characteristics and clinical findings.

27 Gauge (%) (n = 21) 25 Gauge (%) (n = 22) Total (%) (n = 43) P value
Grade
    I 2 (9.5) 6 (27.3) 8 (18.6) 0.22 a
    II 6 (28.6) 4 (18.2) 10 (23.25)
    III 6 (28.6) 9 (40.9) 15 (34.9)
    IV 7 (33.3) 3 (13.6) 10 (23.25)
Age (year)
    Mean ± SD 56.4 ± 8.5 50.3 ± 12.5 53.3 ± 11.2 0.21 *
    Range 32~68 29~65 29~68
Underlying Disease
    Glaucoma 1(4.8) 3(13.6) 4(9.3) 0.61 a
Gender
    Male 10 (47.6) 11 (50) 21 (48.8) 0.89 b
    Female 11 (52.4) 11 (50) 22 (51.2)
Pre-OP BCVA in LogMAR
    Mean ± SD 1.43 ± 0.72 1.72 ± 0.69 1.58 ± 0.72 0.17 *
    Range 0.3~2.8 0.05~2.8 0.05~2.8
Pre-OP IVI Anti-VEGF
    Bevacizumab (Avastin®) 17 (80.95) 17 (77.3) 34 (79.05) 1 a
    Ranibizumab (Lucentis®) 1 (4.75) 2 (9.1) 3 (7.0)
    None 3 (14.3) 3 (13.6) 6 (13.95)
HbA1c
    Mean ± SD 8.54 ± 1.97 8.68 ± 2.13 8.60 ± 2.04 0.88 *
    Range 5.7~14.2 6.1~12.7 5.7~14.2
Duration of DM (year)
    Mean ± SD 8.10 ± 5.85 9.80 ± 6.50 8.97 ± 6.18 0.95 *
    Range 1~20 0.5~20 0.5~20
Pre-operative PRP d 6 (28.6) 8 (36.4) 14 (32.6) 0.82 b

The table mention the pre-surgical condition of 27-gauge, 25-gauge, and their comparison.

Abbreviations: SD: standard deviation, Pre-OP: pre-operative, BCVA: best corrected visual acuity, LogMAR: logarithm of minimal angle of resolution, IVI: intravitreal injection, VEGF: vascular endothelial growth factor, HbA1c: hemoglobin A1c, DM: diabetes mellitus, PRP: pan-retinal photocoagulation.

*: Mann-Whitney U test

a: Fisher’s exact test

b: Pearson chi-square test.

d: Pre-operative PRP and intra-operative PRP spot number showed no statistical significance; thus, they didn’t make significant influence in the operation time.

As for the operative status, all the intraoperative data of patients is listed in Table 2. The 27-gauge and 25-gauge groups did not differ significantly in operation time (p = 0.94), though the operation time in the eyes of the 27-gauge group was shorter than the operation time in the 25-gauge group. The PRP spot number showed no significant difference between these two groups (p = 0.72). There is also no difference in the mean number of iatrogenic retinal breaks (p = 0.35), iatrogenic cataract (p = 0.49), simultaneous cataract surgery (p = 0.49), or the type of endotamponade substance between these two groups (p = 0.55). There was significantly lower rate of using micro forceps in the 27-gauge group (p = 0.004); however, there was no significant trend toward a lower rate of using micro scissors (p = 0.32) and chandelier lighting system (p = 0.52) in the 27-gauge group. At the end of the surgery, the eyes receiving 27-gauge vitrectomy rarely needed sutures for the sclerotomy wound (p = 0.0004).

Table 2. Operative status.

27 Gauge (%) (n = 21) 25 Gauge (%) (n = 22) Total (%) (n = 43) P value
OP time (min)
    Mean ± SD 56.7 ± 19.6 63.7 ± 39.4 60.6 ± 30.9 0.94 *
    Range 33~106 13~170 13~170
Use of instruments
    Micro forceps 14 (66.7) 22 (100) 36 (83.7) 0.004 a
    Micro scissors 1 (4.8) 3 (13.6) 4 (9.3) 0.32 a
    Chandelier 2 (9.5) 3 (13.6) 5 (11.6) 0.52 a
Endotamponade substance
    None 7 (33.3) 7 (31.8) 14 (32.6) 0.55 a
    Room air 0 (0) 2 (9.1) 2 (4.7)
    SF6 6 (28.6) 5 (22.7) 11 (25.6)
    C3F8 5 (23.8) 3 (13.6) 8 (18.6)
    Silicone oil 3 (14.3) 5 (22.7) 8 (18.6)
Wound suture number
    Mean ± SD 0.05 ± 0.21 1.27 ± 1.39 0.67 ± 1.18 0.0004 *
    Range 0~1 0~4 0~4
Iatrogenic break
    Mean ± SD 1.05 ± 2.13 0.86 ± 1.32 0.95 ± 1.77 0.35 *
    Range 0~9 0~4 0~9
Iatrogenic cataract e 1 (4.8) 0 (0) 1 (2.3) 0.49 a
Simultaneous cataract OP e 1 (4.8) 0 (0) 1 (2.3) 0.49 a
PRP spots number d
    Mean ± SD 1887 ±1347 1836 ± 989 1861 ± 1192 0.72 *
    Range 482~6654 0~4351 0~6654

The table mention the intra-operative outcomes of 27-gauge, 25-gauge, and their comparison.

Abbreviations: OP: Operation, min: minute, SD: Standard Deviation, SF6: Sulfur hexafluoride, C3F8: Octafluoropropane, PRP: pan-retinal photocoagulation.

*: Mann-Whitney U test

a: Fisher’s exact test.

d: Pre-operative PRP and intra-operative PRP spot number showed no statistical significance; thus, they didn’t make significant influence in the operation time.

e: One patient in severity grade 4 of TRD received simultaneous cataract surgery, and the other one received cataract surgery due to iatrogenic cataract. Both cases have no much influence on the result of visual acuity improvement.

Details of the post-operative status of the patients are shown in Table 3; there was no significant difference in the final BCVA and changes in BCVA between the 27-gauge and 25-gauge groups after vitrectomy, neither was their difference in post-operative ocular hypertension (p = 0.92) and ocular hypotony (p = 0.51). There was also no difference noted in recurrent VH (p = 1.0), incidence of re-operation related to the surgery (p = 0.26), and time to develop cataract (p = 0.86).

Table 3. Post-surgical results.

27 Gauge (%) (n = 21) 25 Gauge (%) (n = 22) Total (%) (n = 43) P value
Post-OP BCVA in LogMAR
    Mean ± SD 0.79 ± 0.55 0.94 ± 0.69 0.87 ± 0.63 0.58 *
    Range 0~1.7 0~2.8 0~2.8
BCVA improving in LogMAR
    Mean ± SD 0.60 ± 0.67 0.80 ± 0.61 0.70 ± 0.65 0.22 *
    Range -0.4~2.08 -0.02~2.3 -0.4~2.3
IOP
    Ocular hypertension 8 (38.1) 7 (31.8) 15 (34.9) 0.92 c
    Ocular hypotony 0 (0) 1 (4.5) 1 (2.3) 0.51 a
    Total 8 (38.1) 8 (36.4) 16 (37.2) 0.84 c
Recurrent VH 0 (0) 0 (0) 0 (0) 1.00 a
Re-operation 0 (0) 2 (9.1) 2 (4.7) 0.26 a
Time to develop cataract f
    Cataract patient/total patient 3/13 3/18 6/31 0.50 a
    Mean ± SD (month) 5.62 ± 0.77 5.28 ± 1.71 5.42 ± 1.39 0.86 *
    Range (month) 4~6 1~6 1~6

The table mention the post-surgical outcomes of 27-gauge, 25-gauge, and their comparison.

Abbreviations: Post-OP: post-operative, BCVA: best corrected visual acuity, LogMAR: logarithm of minimal angle of resolution, SD: standard deviation, IOP: intraocular pressure, VH: vitreous hemorrhage.

*: Mann-Whitney U test

a: Fisher’s exact test

c: Yate’s continuity correction of Pearson chi-square test.

f: In 27-gauge group, there are six cases received preoperative cataract surgery, and two cases received intraoperative cataract surgery; in 25-gauge group, there are four cases received preoperative cataract surgery.

Discussion

PDR is one of the major causes of visual impairment and eventual loss of sight in diabetic retinopathy patients. It can be further complicated by VH, fibrovascular membrane formation, TRD and CTRRD [17]. The treatment of TRD or CTRRD is challenging for the vitreoretinal surgeon. Generally, multiple strategies including segmentation, delamination and bimanual technique, are used to remove the fibrovascular membrane, and multiple ancillary instruments including micro forceps, micro scissors and bimanual techniques with chandelier lighting system are necessary for surgical success.

The development of the MIVS instrument demonstrates several aspects of advantages over the traditional PPV, like self-sealing transconjunctival wounds, reduced corneal astigmatism, less sclerotomy-related tissue damage, less conjunctival scarring, decreased post-operative inflammation, reduced post-operative hypotony and endophthalmitis [58].

Owing to the improved and powerful endoillumination, intraoperative IOP stabilisation system, ultra-high-speed cutter and wide-angle viewing system, the utilisation of a 27-gauge vitrectomy system is possible in complicated vitrectomy cases [9]. In this comparative study, we also showed a comparable surgical outcome achieved in the 25 and 27-gauge groups.

In this study, a significantly fewer scleral wound suture was noted. Previous literatures had shown the similar trends [13, 1820], and our study further demonstrated a statistical significance. Since in the situation of PDR with TRD, the longer surgical time for fibrotic tissue removal and thus stretching more on scleral wound, which affects wound integrity more, a smaller 27-gauge wound can better demonstrate the non-suture technique in cases of PDR with TRD. Less need of scleral sutures should be especially beneficial for wound healing in the eyes with PDR. Since those eyes are inclined to suffer from corneal epithelial defect either intraoperatively or postoperatively, a smooth ocular surface without suture irritation can help faster recovery of ocular surface. In addition to the universal benefits of smaller wound size, less wound leakage and less post-operative discomfort, we also noticed less use of ancillary instruments in the 27-gauge group. Patients in the 27-gauge group significantly reduce the need for using micro forceps; they can also accomplish the operation without the demands of micro scissors and chandelier lighting system, though without statistical significance. Because of the improved fluidics of 27-gauge system, smaller sphere of influence, the vitrector could partially be served as a micro forceps by engaging the margin of the fibrovascular membrane with suction, and we can perform membrane peeling without micro forceps under some circumstances. Besides, because of the small size of 27-gauge vitrector, there is more chance of the vitrector to gain access into the space between the tissue planes and can be served as a vertical scissors in tissue delamination without exerting much tractional force and making iatrogenic breaks on the adjacent retina. In addition, it can be used for blunt dissection to loosen the adhesive tissues and be served as a pick to elevate tissue. With the multi-functionality of the vitrector, there would be fewer exchanges of instruments, which can shorten the surgical time and the likelihood of iatrogenic breaks. Theoretically, this minimizes the need for micro scissors and the bimanual dissection technique; however, we didn’t show the statistical significance of using micro scissors and chandelier light. This can be explained by the limited case number and that we didn’t further calculate the total number of times we exchanged the instruments within each surgery. However, the vitrector still cannot totally replace the role of micro forceps in the peeling of epiretinal membrane and internal limiting membrane. Besides, in the situation of extremely adherent fibrotic membrane, micro scissors and chandelier lighting system are still necessary in 27-gauge system.

In this comparative study, we noted that the operation time is similar in both groups, if not shorter in the 27-gauge group, which is different from previous reports in which more time is needed in the 27-gauge vitrectomy system in the management epiretinal membrane and PDR [1012]. The difference from previous reports may lie in the fact that eyes with PDR and TRD generally have more liquefied vitreous, thus, the difference of the surgical time for removing the core vitreous between these two systems is less. Moreover, the use of the 27-gauge system allows for lower rates of instrument exchange and therefore, the removal of the fibrotic membrane is more efficient. This shortens the time for membrane removal. A recently published study [12, 20, 21] also showed that there was no difference in operation time for vitrectomy between 27-gauge and 25-gauge vitrectomy systems in the management of RRD. Eyes with RRD, as eyes in PDR with TRD, have a more liquefied vitreous. Core vitrectomy, thus, is no longer the most time-consuming procedure. As a result of the smaller sphere of influence in the 27-gauge vitrectomy system, the shaving of the vitreous gel near the detached retina is much safer and efficient. Henceforth, it is not surprising that the surgical time is not longer in the eyes of PDR with TRD managed with the 27-gauge system.

There are some limitations of this study. First, this is a retrospective study. Second, the case number is small. There is also some power in this study, that all the surgeries were performed by one surgeon, which alleviates the difference of surgical techniques from different surgeons.

Conclusion

In conclusion, the 27-gauge vitrectomy offered comparable surgical results, with less ancillary instrument usage, fewer wound sutures, and similar surgical time. Our study showed the non-inferiority of the 27-gauge over the 25-gauge vitrectomy system in complicated retinal diseases of TRD in PDR patients. However, further prospective study with a larger case number is necessary to validate our conclusion.

Supporting information

S1 Data

(XLSX)

Acknowledgments

I thank the editors from Enago for their expertise and assistance throughout all aspects of our study and for their help in writing the manuscript.

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

The authors received no specific funding for this work.

References

  • 1.Fujii GY, De Juan E Jr., Humayun MS, Chang TS, Pieramici DJ, Barnes A, et al. Initial experience using the transconjunctival sutureless vitrectomy system for vitreoretinal surgery. Ophthalmology. 2002;109(10):1814–20. Epub 2002/10/03. 10.1016/s0161-6420(02)01119-3 . [DOI] [PubMed] [Google Scholar]
  • 2.Fujii GY, De Juan E Jr., Humayun MS, Pieramici DJ, Chang TS, Awh C, et al. A new 25-gauge instrument system for transconjunctival sutureless vitrectomy surgery. Ophthalmology. 2002;109(10):1807–12; discussion 13. Epub 2002/10/03. 10.1016/s0161-6420(02)01179-x . [DOI] [PubMed] [Google Scholar]
  • 3.Eckardt C. Transconjunctival sutureless 23-gauge vitrectomy. Retina. 2005;25(2):208–11. Epub 2005/02/04. 10.1097/00006982-200502000-00015 . [DOI] [PubMed] [Google Scholar]
  • 4.Oshima Y, Wakabayashi T, Sato T, Ohji M, Tano Y. A 27-gauge instrument system for transconjunctival sutureless microincision vitrectomy surgery. Ophthalmology. 2010;117(1):93–102 e2. Epub 2009/11/03. 10.1016/j.ophtha.2009.06.043 . [DOI] [PubMed] [Google Scholar]
  • 5.Spirn MJ. Comparison of 25, 23 and 20-gauge vitrectomy. Curr Opin Ophthalmol. 2009;20(3):195–9. Epub 2009/04/25. 10.1097/ICU.0b013e328329eaea . [DOI] [PubMed] [Google Scholar]
  • 6.Recchia FM, Scott IU, Brown GC, Brown MM, Ho AC, Ip MS. Small-gauge pars plana vitrectomy: a report by the American Academy of Ophthalmology. Ophthalmology. 2010;117(9):1851–7. Epub 2010/09/08. 10.1016/j.ophtha.2010.06.014 . [DOI] [PubMed] [Google Scholar]
  • 7.Okamoto F, Okamoto C, Sakata N, Hiratsuka K, Yamane N, Hiraoka T, et al. Changes in corneal topography after 25-gauge transconjunctival sutureless vitrectomy versus after 20-gauge standard vitrectomy. Ophthalmology. 2007;114(12):2138–41. Epub 2007/12/07. 10.1016/j.ophtha.2007.01.034 . [DOI] [PubMed] [Google Scholar]
  • 8.Nagpal M, Wartikar S, Nagpal K. Comparison of clinical outcomes and wound dynamics of sclerotomy ports of 20, 25, and 23 gauge vitrectomy. Retina. 2009;29(2):225–31. Epub 2009/02/10. 10.1097/IAE.0b013e3181934908 . [DOI] [PubMed] [Google Scholar]
  • 9.Mohamed S, Claes C, Tsang CW. Review of Small Gauge Vitrectomy: Progress and Innovations. J Ophthalmol. 2017;2017:6285869. Epub 2017/06/08. 10.1155/2017/6285869 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Mitsui K, Kogo J, Takeda H, Shiono A, Sasaki H, Munemasa Y, et al. Comparative study of 27-gauge vs 25-gauge vitrectomy for epiretinal membrane. Eye (Lond). 2016;30(4):538–44. Epub 2016/01/09. 10.1038/eye.2015.275 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Naruse S, Shimada H, Mori R. 27-gauge and 25-gauge vitrectomy day surgery for idiopathic epiretinal membrane. BMC Ophthalmol. 2017;17(1):188. Epub 2017/10/12. 10.1186/s12886-017-0585-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Naruse Z, Shimada H, Mori R. Surgical outcomes of 27-gauge and 25-gauge vitrectomy day surgery for proliferative diabetic retinopathy. Int Ophthalmol. 2019;39(9):1973–80. Epub 2018/10/05. 10.1007/s10792-018-1030-z . [DOI] [PubMed] [Google Scholar]
  • 13.Otsuka K, Imai H, Fujii A, Miki A, Tagami M, Azumi A, et al. Comparison of 25- and 27-Gauge Pars Plana Vitrectomy in Repairing Primary Rhegmatogenous Retinal Detachment. J Ophthalmol. 2018;2018:7643174. Epub 2018/07/27. 10.1155/2018/7643174 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Shi L, Huang YF. Postvitrectomy diabetic vitreous hemorrhage in proliferative diabetic retinopathy. J Res Med Sci. 2012;17(9):865–71. Epub 2013/07/05. [PMC free article] [PubMed] [Google Scholar]
  • 15.Huang CH, Hsieh YT, Yang CM. Vitrectomy for complications of proliferative diabetic retinopathy in young adults: clinical features and surgical outcomes. Graefes Arch Clin Exp Ophthalmol. 2017;255(5):863–71. Epub 2017/01/08. 10.1007/s00417-016-3579-4 . [DOI] [PubMed] [Google Scholar]
  • 16.Zhao XY, Xia S, Chen YX. Antivascular endothelial growth factor agents pretreatment before vitrectomy for complicated proliferative diabetic retinopathy: a meta-analysis of randomised controlled trials. Br J Ophthalmol. 2018;102(8):1077–85. Epub 2017/12/17. 10.1136/bjophthalmol-2017-311344 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Wong TY, Cheung CM, Larsen M, Sharma S, Simo R. Diabetic retinopathy. Nat Rev Dis Primers. 2016;2:16012. Epub 2016/05/10. 10.1038/nrdp.2016.12 . [DOI] [PubMed] [Google Scholar]
  • 18.Sborgia G, Niro A, Sborgia L, Grassi MO, Gigliola S, Romano MR, et al. One-year outcomes of 27-gauge versus 25-gauge pars plana vitrectomy for uncomplicated rhegmatogenous retinal detachment repair. Int J Retina Vitreous. 2019;5:13. Epub 2019/06/07. 10.1186/s40942-019-0164-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Mori R, Naruse S, Shimada H. Comparative study of 27-gauge and 25-gauge vitrectomy performed as day surgery. Int Ophthalmol. 2018;38(4):1575–82. Epub 2017/07/04. 10.1007/s10792-017-0625-0 . [DOI] [PubMed] [Google Scholar]
  • 20.Rizzo S, Polizzi S, Barca F, Caporossi T, Virgili G. Comparative Study of 27-Gauge versus 25-Gauge Vitrectomy for the Treatment of Primary Rhegmatogenous Retinal Detachment. J Ophthalmol. 2017;2017:6384985. Epub 2017/04/04. 10.1155/2017/6384985 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Li J, Zhao B, Liu S, Li F, Dong W, Zhong J. Retrospective Comparison of 27-Gauge and 25-Gauge Microincision Vitrectomy Surgery with Silicone Oil for the Treatment of Primary Rhegmatogenous Retinal Detachment. J Ophthalmol. 2018;2018:7535043. Epub 2018/10/12. 10.1155/2018/7535043 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Michael Mimouni

7 Dec 2020

PONE-D-20-33300

Comparison of 27-gauge and 25-gauge vitrectomy in the management of tractional retinal detachment secondary to proliferative diabetic retinopathy

PLOS ONE

Dear Dr. Chen,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jan 11 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Michael Mimouni

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2.We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

3. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

4.Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians.

In addition, Please clarify the context in which consent was obtained, and specify whether patients provided:

    1) Consent to use their medical records/samples used in research

    2) Consent to undergo the procedure

    3) Consent to take part in the study reported in this manuscript.

If the need for additional consent was waived by the ethics committee, please include this information.

5. In the ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records/samples used in your retrospective study, including: a) whether all data were fully anonymized before you accessed them; b) the date range (month and year) during which patients' medical records/samples were accessed.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: I Don't Know

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Review:

PONE-D-20-33300

Comparison of 27-gauge and 25-gauge vitrectomy in the management of tractional retinal detachment secondary to proliferative diabetic retinopathy

This study was well conducted, and the manuscript is well written, but there are several points of concern. First, a retrospective small sample size of 43 patients. Secondly, the findings of this study are not novel and there more than a few previous studies to compare 27 gauge to 25-gauge vitrectomy for RRD and TRD.

Few minor points:

1. Randomization: How patients were randomized for both groups? If there were no randomization how the author explains the similarity between both groups?

2. Lines 135-137: “There was significantly lower rate of using micro forceps in the 27-gauge group (p = 0.004), and a trend toward a lower rate of using micro scissors (p = 0.32) and chandelier lighting system (p = 0.52) in the 27-gauge group.” P=0.32 and 0.52 is not a trend. Indeed, the usage of 27 gauge instead of 25 gauge in theory should make surgeon use less intra ocular devices, but the author did not demonstrate it in this current study.

Reviewer #2: Comparison of 27-gauge and 25-gauge vitrectomy in the management of tractional retinal detachment secondary to proliferative diabetic retinopathyMaterials and Methods

Here are my comments:

1) In the methods and materials, you’ve discussed the status of pre-operative treatment including Anti-VEGF, you have not mentioned the pre-operative treatment with laser pan photocoagulation PRP which usually shorten the time of surgery – if previously done- and also make the vitrectomy easier for some extent

2) Regarding post-operative BCVA improvement, how did you define the improvement especially in cases with combined PPV and cataract surgery?

3) Have you noticed any significant difference in post vitrectomy cataract development between 25G and 27G?

4) As the cutter and the light pipe are thinner in 27G, have you noticed more bending of the instruments in 27G than that of 27G, or there was no significant difference?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Mar 25;16(3):e0249139. doi: 10.1371/journal.pone.0249139.r002

Author response to Decision Letter 0


25 Jan 2021

Response to Reviewers

We thank all the reviewers for giving us the suggestions and opportunity to submit a revised manuscript and hope that this improved manuscript is acceptable for publication in the journal of PLOS ONE®.

Response to Reviewer # 1:

1. Comment: A retrospective small sample size of 43 patients

Author response: Thank you for pointing this out. Because of the improved care of diabetes mellitus in Taiwan, the number of TRD secondary to PDR is decreasing, besides, we only enroll cases of TRD with macular involvement, which explained the limited case number. However, it is beyond denial; this is a weak point of this study, and we had mentioned the paragraph discussing about the limitations of the study.

2. Comment: The findings of this study are not novel and there more than a few previous studies to compare 27 gauge to 25-gauge vitrectomy for RRD and TRD.

Author response: Most of the previous comparative studies of 27- and 25-gauge vitrectomy were discussing about RRD. I believe there are still some findings in this manuscript that can support us to manage more complicated retinal disease like TRD secondary to PDR by choosing 27-gauge vitrectomy.

3. Comment: How patients were randomized for both groups? If there were no randomization how the author explains the similarity between both groups?

Author response: Since this is a retrospective study, there was no randomization. The similarity between these two groups were because all the cases of 27-gauge were cases having the surgery after August 2018 (the cases were collected from March 2018 to January 2019), when 27-gauge vitrectomy was available in our hospital, before that, we use 25-gauge vitrectomy for PDR with TRD. Since those patients were all DM with TRD. It is of no surprise patients of this disease had similar background conditions and similar demographic data.

4. Comment: Lines 135-137: “There was significantly lower rate of using micro forceps in the 27-gauge group (p = 0.004), and a trend toward a lower rate of using micro scissors (p = 0.32) and chandelier lighting system (p = 0.52) in the 27-gauge group.” p = 0.32 and 0.52 is not a trend. Indeed, the usage of 27 gauge instead of 25 gauge in theory should make surgeon use less intra ocular devices, but the author did not demonstrate it in this current study.

Author response: Though 27G vitrector can significantly reduce the use of micro forceps. We still cannot show the trend of less use in micro scissors and chandelier lighting system, though we did feel that the timing of using micro scissors is less. The possible explanation is that, first, the case number is not large enough, which could not show statistical significance, and second, though we still use micro scissors in 27-gauge system in some complicated cases, the total times in each surgery using micro scissor may still be less, however, we need another study to confirm this. In the revised manuscript, I will change the sentence of “trend” to “no significant trend” (Lines 140-141), instead, we will discuss why we did not show significantly less usage of micro scissors in this study (Lines 184-188).

Response to Reviewer # 2:

1. Comment: In the methods and materials, you’ve discussed the status of pre-operative treatment including Anti-VEGF, you have not mentioned the pre-operative treatment with laser pan photocoagulation PRP which usually shorten the time of surgery – if previously done- and also make the vitrectomy easier for some extent

Author response: Thank you for the reviewer point out the weak point of this study. In the revised manuscript, the information of previous PRP will be added. We will add the pre-operative PRP, intra-operative PRP spot number (Lines 136-137, Table 1 and 2), and thus, this PRP number cannot influence total operation time (Lines 299-300, Line 308-309).

2. Comment: Regarding post-operative BCVA improvement, how did you define the improvement especially in cases with combined PPV and cataract surgery?

Author response: There are only two cases had received simultaneous cataract surgery, without statistical significance. One of them is in the severity stage 4 of TRD, and cataract is not an important factor to influence the visual acuity improvement. The other one received cataract surgery due to intra-operative iatrogenic cataract, and this cannot influence the visual acuity improvement. We added the simultaneous cataract surgery (Lines 138-139, Table 2) and further discussed this. (Lines 306-308)

3. Comment: Have you noticed any significant difference in post vitrectomy cataract development between 25G and 27G ?

Author response: In the 27-gauge group, there were 10 cases receiving cataract surgery 6 months later or longer after, and 3 cases received cataract surgery at 4, 4, 5 months. While in the 25-gauge group, there were 15 cases receiving cataract surgery 6 months later or longer after, and 3 cases received cataract surgery at 1, 1, 3 months. There are no significant difference between 2 groups in cataract development. We will add time to develop cataract. (Lines 315-317, Table3)

4. Comment: As the cutter and the light pipe are thinner in 27G, have you noticed more bending of the instruments in 27G than that of 27G, or there was no significant difference?

Author response: We did notice there was more chance of instrument bending in the 27-gauge system when we initially use 27-gauge system. However, after a short learning curve, bending of instrument seldom happens. To avoid bending of instruments, you should not rotate the eye ball too much with the instrument as we used to do with 25- or 23-gauge system. To address the far peripheral lesions, use indentation, instead of rotating the eye ball.

Attachment

Submitted filename: 2021.01.25 Response to Reviewers.docx

Decision Letter 1

Michael Mimouni

12 Mar 2021

Comparison of 27-gauge and 25-gauge vitrectomy in the management of tractional retinal detachment secondary to proliferative diabetic retinopathy

PONE-D-20-33300R1

Dear Dr. Chen,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Michael Mimouni

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

PLOS ONE does not reject manuscripts based on perceived impact or significance. Therefore, the manuscript is suitable for publication. 

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This study is well designed, and the manuscript is well written. But, unfortunately, this study has a very small sample size, without novel or significant findings.

Reviewer #2: (No Response)

Acceptance letter

Michael Mimouni

16 Mar 2021

PONE-D-20-33300R1

Comparison of 27-gauge and 25-gauge vitrectomy in the management of tractional retinal detachment secondary to proliferative diabetic retinopathy

Dear Dr. Chen:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Michael Mimouni

Academic Editor

PLOS ONE


Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES